

CannabiStada Extrakt THC 25/CBD 1 DK, 30 ml solution

Product 00183425 **Batch** 25-0093-VA **Batch no.** 25-0093-VA
Date of manufacture 02/2025 **Expiry date** 01/2027
Customer: STADapharm GmbH
Variant: Control CY: Deutschland CU: STADapharm

Test	Method	Specification	Result
Appearance	visual	light yellow to light brownish liquid	complies
Relative density	Ph.Eur.2.2.5	0.935 - 0.965	0.954
Refractive index	Ph.Eur.2.2.6	1.446 - 1.458	1.453
Water content	Ph.Eur.2.5.12	≤ 0.5 %	< 0.1 %
Water content	M0040	≤ 0.5 %	< 0.1 %
Residual solvents Ethanol	Ph.Eur. 2.4.24	≤ 5000 ppm	1555 ppm
Residual solvents Ethanol	M0023	≤ 5000 ppm	1555 ppm
Cannabinole	DAB	≤ 2.5 %	0.1 %
Cannabinole	M0024	≤ 2.5 %	0.1 %
Tetrahydrocannabinole Identification UHPLC	M0024	has to comply	complies
Tetrahydrocannabinole Assay UHPLC	M0024	22.5 - 27.5 mg/ml	25.5 mg/ml
Cannabidiol Assay UHPLC	M0024	≤ 1 mg/ml	< 1 mg/ml
Microbiology TAMC	Ph.Eur. 2.6.12/2.6.31	≤ 10 ⁴ CFU/ml	complies
Microbiology TYMC	Ph.Eur. 2.6.12/2.6.31	≤ 10 ² CFU/ml	complies
Microbiology Bile tolerant gram negative bacteria	Ph.Eur. 2.6.12/2.6.31	≤ 10 ² CFU/ml	complies
Microbiology Escherichia coli	Ph.Eur. 2.6.12/2.6.31	absent/ml	complies
Microbiology Salmonellae	Ph.Eur. 2.6.12/2.6.31	absent/25ml	complies
Manufacture	documentary	has to comply	complies

Closed by: H. Ziehr

The batch has been tested according to GMP-Guidelines and complies to the specification.

Date / Signature: 04/04/2025

Dr. Holger Ziehr
Qualified Person

- End of Certificate -

Batch Quality Certificate

(Confirmation concerning Annex 16 EU GMP-Guide)

Product:	CannabiStada Extrakt THC 25/CBD 1 DK, 30 ml solution
Customer:	STADApHarm GmbH, Germany
MA-number/reference document:	n/a
Package size:	30 ml extract
Batch no. (finished product):	25-0093-VA
Batch (finished product):	25-0093-VA
Date of manufacture (dd/mm/yyyy):	04.02.2025
Expiry date:	01/2027
Batch STADA (bulk):	25-0093-VA
Batch no. manufacturer (bulk):	COP-25-0093-V-A
Batch size (bulk):	---
Site of bulk production:	Valcon Medical A/S., Denmark
Site of packaging:	Valcon Medical A/S., Denmark
Quantity released:	1 092 packages

☒ The API manufacturer(s) is part of STADA Arzneimittel AG's current API supplier qualification programme. It is confirmed that this API manufacturer(s) complies with the relevant guidelines and requirements for GMP of API manufacturing.

☒ Release to market:

I hereby certify that all the manufacturing stages of this batch of finished product have been carried out in full compliance with the GMP requirements of the EU and with the requirements of the Marketing Authorisation of the destination country.

☐ Release for shipment:

I hereby confirm that the manufacturing stages referred to in the Technical Quality Agreement have been carried out in full compliance with the GMP requirements of the EU and the terms described in the Agreement for ensuring compliance with the requirements of the Marketing Authorisation(s) as provided by [Contract Giver/manufacturer certifying and releasing the batch].

Deviations concerning the quality and release of the product:

☐ No deviation occurred ☐ Yes, any additional information are enclosed

Comments/remarks:

Deviation without impact on product quality.

Date: 04.04.2025


Dr. H. Ziehr
Qualified Person

STADA Arzneimittel AG

Stadastr. 2 - 18 • 61118 Bad Vilbel
Telefon +49 6101 603-0
Telefax +49 6101 603-259

E-Mail: info@stada.de
www.stada.com

Vorstand:
Peter Goldschmidt (Vorsitzender)
Simone Berger
Miguel Pagan Fernandez
Boris Döbler

Aufsichtsrat:
Dr. Günter von Au (Vorsitzender)

Bankkonten:
Deutsche Bank AG, 60311 Frankfurt am Main
IBAN: DE13 5007 0010 0096 0120 00
BIC: DEUTDEFF

Postbank AG, 60288 Frankfurt am Main
IBAN: DE36 5001 0060 0009 2186 07
BIC: PBNKDEFF

Sitz der Gesellschaft:
Bad Vilbel

Registergericht:
Frankfurt am Main HRB 71290

USt-IdNr.: DE 112589604